

日本プロテオーム学会の皆さま

このたび International Journal of Proteomics では「Proteomics-Based Disease Biomarkers」と題して特集を組むことになりました。

プロテオーム解析の分野ではバイオマーカー開発は主要なトピックスであり、論文・学会において多くの発表が行われています。バイオマーカーは医療現場のみならず、創薬のプロセスにおいても重要であるとの認識から、さまざまな分野の研究者が開発に携わっており、学際的な研究テーマとなっています。同時に、研究体制の問題、技術開発の問題、実用化の問題など、多くの点で議論がつきないところであり、毎年のように新しい展開がみられています。

プロテオーム解析のアプローチでバイオマーカー開発を推進している方からの、オリジナル論文、総説などをお待ちしています。日本・アジア地域からの情報発信としてよい機会だと思いますので、御考慮いただければ幸いです。

International Journal of Proteomics で発表されている「Call for Papers」を添付しました。

どうかよろしく申し上げます。

平成23年1月29日

近藤格

創薬プロテオーム研究分野

国立がん研究センター研究所

Special Issue on Proteomics-Based Disease Biomarkers

Call for Papers

Sequencing of the human genome has greatly impacted the proteomics-based analysis of disease by providing a framework for understanding the proteome of diseased cells, tissues, and biological fluids. There is much interest in applying proteomics technologies to discover processes at the protein level that are involved in various diseases, to uncover new biomarkers that correlate with the early diagnosis of diseases and to accelerate the development of new therapeutic targets. New proteomics technologies are being developed in order to facilitate both the high-throughput and high-sensitivity requirements of disease-related applications of proteomics. These innovative technologies have greatly enhanced our ability to separate and characterize complex protein mixtures. They have also aided our ability to identify proteins with greater sensitivity, thereby providing the groundwork for future scientific breakthroughs and possibly providing the framework for the development of personalized disease therapy. We invite investigators to contribute original research articles as well as review articles that will stimulate the continuing efforts to understand disease subtypes at the protein level, the development of protein-based biomarkers for the early detection of disease, the development of treatment modalities based upon disease-specific protein biomarker signatures, and the protein- biomarker-based evaluation of therapeutic efficacy. We are interested in articles that explore aspects of protein-based biomarkers in humans and also in animal models of disease. Potential topics include, but are not limited to:

- Protein-based signatures of disease subtypes, with emphasis on the expression of different protein biomarkers reflective of a given disease subtype
- Protein-based biomarkers for the early detection of diseases, including potential disease-specific post-translational modifications of proteins
- Latest technologies for the elucidation of protein signatures of disease, including autoantibodies
- Role of protein biomarkers in the process of drug development
- Role of protein biomarkers in the evaluation of therapeutic efficacy

- Role of protein biomarkers in predicting and monitoring side effects of therapeutic intervention

Before submission authors should carefully read over the journal's Author Guidelines, which are located at <http://www.hindawi.com/journals/ijpro/guidelines.html>. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at <http://mts.hindawi.com/> according to the following timetable:

Manuscript Due	June 1, 2011
First Round of Reviews	September 1, 2011
Publication Date	December 1, 2011

Lead Guest Editor

David E. Misek, Department of Surgery, University of Michigan, Ann Arbor, MI, 48109, USA; dmisek@umich.edu

Guest Editors

Tadashi Kondo, Division of Pharmacoproteomics, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan; takondo@ncc.go.jp

Mark W. Duncan, Division of Endocrinology, Metabolism and Diabetes, School of Medicine, University of Colorado Denver, Aurora, CO 80045, USA; Obesity Research Center, College of Medicine, King Saud University, Riyadh, Saudi Arabia; mark.duncan@ucdenver.edu